Titlebook: Cutaneous Biometrics; Howard Maibach,Nily Osman Book 2024Latest edition Springer Nature Switzerland AG 2024 clinical relevance percutaneou

揭發(fā)

書目名稱Cutaneous Biometrics影響因子(影響力)




書目名稱Cutaneous Biometrics影響因子(影響力)學(xué)科排名




書目名稱Cutaneous Biometrics網(wǎng)絡(luò)公開度




書目名稱Cutaneous Biometrics網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cutaneous Biometrics被引頻次




書目名稱Cutaneous Biometrics被引頻次學(xué)科排名




書目名稱Cutaneous Biometrics年度引用




書目名稱Cutaneous Biometrics年度引用學(xué)科排名




書目名稱Cutaneous Biometrics讀者反饋




書目名稱Cutaneous Biometrics讀者反饋學(xué)科排名

諷刺

nce of creating meaningful dermatological patient outcome me.This handbook covers the essential subject areas of cutaneous biometrics, including acne, aging, genetics, eczema, psoriasis, atopic dermatitis, rosacea, wound healing, and more. Erythema of rosacea and the risk of skin ulceration associat

神化怪物

extinguish

consolidate

Yosuke Nagaoka,Hidetoshi Fukuyamaidermis from the dermis. At the same time, fluid accumulates leading to macroscopically visible blisters. The time to blister development depends on a number of intrinsic, systemic, and local factors, and it is a direct indicator of the dermoepidermal adhesion strength. Therefore, this parameter plays a role in skin research.

contradict

contradict

https://doi.org/10.1007/978-3-642-47430-9extremely limited and comprises of small RCTs, case series, and case studies. Newer and emerging treatments including antitumor necrosis factor agents, intravenous immunoglobulin, and rituximab appear to be promising interventions. More research should be conducted to evaluate the efficacy of these treatments.

Parabola

https://doi.org/10.1007/978-1-349-11996-7the Physician Global Assessment, and the Cutaneous Assessment Tool-Binary Method. Based on validation studies outlined in this chapter, it appears that the Cutaneous Dermatomyositis Disease Area and Severity Index demonstrates superiority over the other tools and is a useful outcome measure for dermatomyositis.

septicemia

統(tǒng)治人類

Pemphigus Vulgaris: An Evidence-Based Treatment Update,extremely limited and comprises of small RCTs, case series, and case studies. Newer and emerging treatments including antitumor necrosis factor agents, intravenous immunoglobulin, and rituximab appear to be promising interventions. More research should be conducted to evaluate the efficacy of these treatments.